Given that miR-17-5p expression is significantly lower in pre-treatment tumor biopsies from EAC patients who subsequently have a poor response to neoadjuvant CRT ([23] and Figure 4A), we hypothesised that C6orf120 and PRKACB would consequently be upregulated in poor responder tumors. The gene discussed is PRKACB; the disease is neoplasm.